TITLE

Bioenvision To Begin European Marketing Of Modrefen

PUB. DATE
July 1999
SOURCE
Worldwide Biotech;Jul99, Vol. 11 Issue 7, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the announcements of Bioenvision Incorporated. Plans for Modrefen; Clinical trial of purine nucleoside anti-cancer agent, clofarabine; Company's research agreement signing with the Royal Free and University College Medical School.
ACCESSION #
2107047

 

Related Articles

  • Bioenvision plans new breast cancer studies with Modrenal.  // PharmaWatch: Cancer;January 2004, Vol. 3 Issue 1, p6 

    Reports on the plan of Bioenvision Inc. to conduct studies in Great Britain in pre-menopausal, pre-operative and post-menopausal women for the company's lead breast cancer treatment, Modrenal. Aim of the post-menopausal phase IV study; Clinical benefit rates of the drug.

  • Genzyme's Hylastan fizzles; Synvisc-One efforts continue. Osborne, Randall // Medical Device Daily;7/9/2007, Vol. 11 Issue 130, p2 

    The article deals with Genzyme's hylastan and synvisc-one drugs, indicated to relieve osteoarthritis knee pain. While hylastan failed to beat steroids in a pivotal trial study, the company was unmoved as its synvisc-one awaits a pending approval in the U.S. and Europe. Bo Piela of Genzyme...

  • Bioenvision drug performing well in leukemia.  // PharmaWatch: Cancer;May 2005, Vol. 4 Issue 5, p11 

    Reports that British and US-based biopharmaceuticals firm Bioenvision Ltd has reported positive interim results from ongoing clinical studies of its Genzyme Corp. co-developed drug, clofarabine, in pediatric and adult acute leukemia trials. One set of interim results are from a phase II...

  • Bioenvision's trial of clofarabine in adult acute leukemia exceeds expectations.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p9 

    Announces the Bioenvision Inc.'s sponsored clinical trial of clofarabine as first line treatment in older adults with acute myeloid leukemia. Number of patients enrolled in the study; Evaluation of the safety and efficacy of clofarabine; Product development.

  • Bioenvision to initiate trials of breast cancer drug.  // PharmaWatch: Cancer;September 2004, Vol. 3 Issue 9, p4 

    Reports on Bioenvision's clinical trial of its drug Modrenal in treating pre- and post-menopausal forms of breast cancer. Mechanism of action of the drug.

  • Bioenvision: clofarabine holds promise as new AML therapy.  // PharmaWatch: Cancer;September 2004, Vol. 3 Issue 9, p12 

    Reports on phase II clinical trial of Bioenvision's drug clofarabine for acute myelocytic leukemia. Mechanism of action.

  • CLINICAL TRIALS NEWS.  // Applied Clinical Trials;Jan2006, Vol. 15 Issue 1, p18 

    The article offers news briefs related to clinical trials. Bioenvision Inc. has announced that it has started a muiticenter Phase IV trial of Modrenal in postmenopausal women who have failed prior aromatase inhibitor therapy. Merck's Gardasil vaccine has prevented 100% of high-grade cervical...

  • Bioenvision: clofarabine holds promise as new AML therapy.  // PharmaWatch: Monthly Review;September 2004, Vol. 3 Issue 9, p7 

    Reports on the successful preliminary Phase II clinical trial of Bioenvision's lead oncology compound, clofarabine. Long-term outlook for acute myeloid leukemia (AML) patients; Focus of clofarabine on elderly AML patients; Properties of the drug.

  • Bioenvision files IND application for Modrenal in prostate cancer treatment.  // PharmaWatch: Cancer;April 2004, Vol. 3 Issue 4, p13 

    Reports that Bioenvision Inc. has filed an Investigational New Drug application to consider the efficacy of Modrenal (trilostane) in patients with androger-independent prostate cancer. Design of the phase II open label clinical trial of Modrenal; Approval of Modrenal for the treatment of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics